Empagliflozin users had 741 events compared to 712 in the DPP4i group, corresponding to a non-significant HR of 1.04. For DR progression, empagliflozin users experienced fewer events (158) than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback